Sumitomo Pharma Co (TYO:4506) unveiled "Boost 2028" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier "Reboot 2027" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.

The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.

Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.

The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.